EXICURE INC
XCURNASDAQTrading Snapshot
- Day Range
- $1.12 β $1.16
- 52-Week Range
- $1.05 β $9.48
- Volume
- $4.65B
- Avg Volume
- $4.66B
- Shares Outstanding
- 6.4M
- Next Earnings
- Dec 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $287,071
- P/E Ratio
- -0.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.30
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4.5%
Why Investors Own XCUR
- βHigh-growth profile β revenue up +12.3% YoY with expanding US Equity exposure.
- βHealthy economics β 31% gross margin and 16% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
EXICURE INC
XCURAbout EXICURE INC
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement
WILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (βExicureβ or the βCompanyβ) today announced that, on September 10, 2026, it received a letter from the Listing Qualifications Department

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (βExicureβ or the βCompanyβ) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (βGPCR

Exicure Announces Board and Committee Changes
WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions approved by the Compa